MedPage Today Action Points
o Explain to interested patients and caregivers that the transdermal patch for Alzheimer's disease is still an investigational drug that has not been approved by the FDA.
o This study was published as an abstract and presented orally at a conference. These data and conclusions should be considered to be preliminary as they have not yet been reviewed and published in a peer-reviewed publication.
MADRID, July 20 -- An investigational transdermal patch to deliver an Alzheimer's drug appears to be as effective as currently marketed Exelon (rivastigmine) capsules and eases compliance worries, researchers said here.
"The rivastigmine patch provides similar efficacy to the highest capsule doses, and was superior to placebo," said Bengt Winblad, MD, of Karolinska Institute in Stockholm reported at the at the International Conference on Alzheimer's Disease and Related Disorders here.
"A transdermal patch may prove to be the best way to deliver rivastigmine to treat Alzheimer's disease," Dr. Winblad said in presenting the results of the IDEAL (Investigation of TransDermal Exelon in Alzheimer's disease).
For full article, please visit: